image credit: vecstock / Freepik

Accelerating Lentivirus Manufacturing: Choosing the Right Plasmid Manufacturing Platform

Plasmid DNA is a critical raw material that is required for the manufacturing of virus-based gene therapy and gene-modified cell therapies. The current challenges with the supply of plasmid DNA varies depending on its end use, but usually production capacity, costs of manufacturing and meeting regulatory compliance are the common denominators. Join this webinar to hear from Philippe Ledent, Chief Scientific Director at Xpress Biologics, now part of Sartorius and Rakel Lopez de Maturana, Qualified Person & Regulatory Affairs Director at VIVEbiotech discuss how to ensure gain of time and success of lentiviral-based therapies from process development up to market approval.

Read More on Biopharm International